



Domain Therapeutics announces successful completion of the first milestone in its Research Agreement with Takeda Pharmaceutical

Strasbourg, France, November 4, 2009 - Domain Therapeutics, a drug discovery company focused on G Protein-Coupled Receptors (GPCRs), announces today that it has successfully completed the first milestone in its research agreement with Takeda Pharmaceutical. This research agreement initially concerns the use of Domain's DTect-All™ technology for the discovery of novel drug candidates for GPCRs of interest to Takeda.

"Achievement of this milestone is a firm confirmation of the ability of Domain Therapeutics' unique technology to address difficult GPCRs," said Pascal Neuville, CEO of Domain Therapeutics. "We are confident that its continued use will further the goals of this on-going research program."

DTect-All™ is Domain's proprietary technology platform dedicated to identification of GPCR ligands, more specifically allosteric modulators. DTect-All™ addresses every GPCR including challenging ones such as orphan and peptidic receptors.

For this milestone, Domain will receive an undisclosed success fee.

About G Protein-Coupled Receptors (GPCRs)

GPCR targets account for 40-50% of currently marketed drugs and for more than \$30B in annual sales. Their potential remains tremendous, as more than 300 are still unexploited because difficult to address. To tackle these, there is a need for new technologies, for example ones able to address orphan and peptidic GPCRs. Another challenge is the identification of allosteric modulators, a new class of GPCR ligands that are considered safer than standard agonist/antagonist molecules. Domain Therapeutics' DTect-All™ technology addresses both these unmet needs and will enable the company to participate broadly in the rapidly growing GPCR drug discovery efforts.

About Domain Therapeutics S.A.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics uses DTect-All™, its innovative and proprietary technology platform, to identify allosteric modulators, including Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. The platform addresses difficult GPCRs such as orphan and peptidic receptors. The company's pipeline is composed of new chemical entities, ranging from hits to preclinical candidates, and targeting hot GPCRs for leading indications such as schizophrenia, Parkinson's disease, and diabetes.

Contact for Media & Analysts

Andrew Lloyd & Associates

Neil Hunter/Andrew Lloyd

neil@ala.com/allo@ala.com

Tel: +44 1273 675 100
